Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Assunto principal
Intervalo de ano de publicação
1.
Nanoscale ; 12(25): 13757-13770, 2020 Jul 02.
Artigo em Inglês | MEDLINE | ID: mdl-32573587

RESUMO

New lipid-based nanomaterials and multi-target directed ligands (MTDLs) based on sterically hindered phenol, containing a quaternary ammonium moiety (SHP-s-R, with s = 2,3) of varying hydrophobicity (R = CH2Ph and CnH2n+1, with n = 8, 10, 12, 16), have been prepared as potential drugs against Alzheimer's disease (AD). SHP-s-R are inhibitors of human cholinesterases with antioxidant properties. The inhibitory potency of SHP-s-R and selectivity ratio of cholinesterase inhibition were found to significantly depend on the length of the methylene spacer (s) and alkyl chain length. The compound SHP-2-16 showed the best IC50 for human AChE and the highest selectivity, being 30-fold more potent than for human BChE. Molecular modeling of SHP-2-16 binding to human AChE suggests that this compound is a dual binding site inhibitor that interacts with both the peripheral anionic site and catalytic active site. The relationship between self-assembly parameters (CMC, solubilization capacity, aggregation number), antioxidant activity and a toxicological parameter (hemolytic action on human red blood cells) was investigated. Two sterically hindered phenols (SHP-2-Bn and SHP-2-R) were loaded into L-α-phosphatidylcholine (PC) nanoparticles by varying the SHP alkyl chain length. For the brain AChE inhibition assay, PC/SHP-2-Bn/SHP-2-16 nanoparticles were administered to rats intranasally at a dose of 8 mg kg-1. The Morris water maze experiment showed that scopolamine-induced AD-like dementia in rats treated with PC/SHP-2-Bn/SHP-2-16 nanoparticles was significantly reduced. This is the first example of cationic SHP-phospholipid nanoparticles for inhibition of brain cholinesterases realized by the use of intranasal administration. This route has promising potential for the treatment of AD.


Assuntos
Doença de Alzheimer , Administração Intranasal , Doença de Alzheimer/tratamento farmacológico , Animais , Inibidores da Colinesterase/farmacologia , Lipídeos/uso terapêutico , Fenol/uso terapêutico , Fenóis , Ratos , Relação Estrutura-Atividade
2.
Medchemcomm ; 9(12): 2106-2120, 2018 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-30746069

RESUMO

Here, we present an approach to novel "hybrid" biologically active compounds based on a combination of sterically hindered phenol and ammonium pharmacophores in a single molecule. The novel target ammonium salts were obtained by the reaction of 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(2-(dimethylamino)alkyl)propanamide with aliphatic bromides or by the reaction of phosphorylated methylenequinones with diamines followed by alkylation with organic bromides. A series of twenty-three novel multifunctional ammonium salts that contain a sterically hindered phenolic fragment were assessed for antimicrobial, cytotoxic and antioxidant activity. The compounds exhibited antimicrobial activity against Staphylococcus aureus ATCC 209p, Bacillus cereus ATCC 8035, Escherichia coli CDC F-50, Pseudomonas aeruginosa ATCC 9027, Aspergillus niger BKMF-1119, Trichophyton mentagrophytes var. gypseum 1773, and Candida albicans 855-653 in the concentration range of 442-0.70 µM. The maximum activity of an ammonium salt among all the types of structure was observed in cases in which a decyl radical was present on the onium nitrogen atom. The most active compounds exhibited antioxidant activity at levels of 0.25 and 0.50 mM and did not display cytotoxic properties towards WI-38 (human embryonic lung cells) and Chang liver (human liver cells) cell lines in the concentration range of 0.70-11.3 µM.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...